Technical Data
M9758-08K
MOG (Myelin Oligodendrocyte Glycoprotein)
Description:
Myelin-oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin (Ig) superfamily, exclusively expressed in the central nervous system (CNS). MOG is an intrinsic membrane protein characterized by a N-terminal extracellular immunoglobulin- like variable (Ig-like V-type) domain, two hydrophobic transmembrane domains and a cytoplasmic C-terminal region. The N-terminal MOG domain has strong homology with the N- terminus of butyrophilin, a protein expressed in the lactating mammary gland. Human MOG gene is localized to chromosome 6p22-p21.3 (band C of mouse chromosome 17) at the distal end of the MHC class Ib region. Despite the similar names, oligodendrocyte-myelin glycoprotein (OMG) is a separate protein encoded within a large intron of the NF1 gene. The 2 glycoproteins are associated specifically with oligodendrocytes and myelin, but have quite different roles in myelinogenesis and are structurally unrelated. MOG is an intrinsic membrane molecule with 2 transmembrane domains, whereas OMG is anchored in the outer leaflet of the plasma membrane through a glycophospholipid tail. OMG belongs to the family of proteins with a series of tandem leucine-rich repeats, while MOG is a member of the Ig superfamily.

MOG contains nine exons and eight separating introns, giving rise to at least eight alternatively spliced variants encoding for the MOG-alpha1-4 and MOG-beta 1-4 isoforms (16-26kD). The different MOG isoforms may interact to form homo- and heterodimers and trimers (55 and 78kD). During the last step of myelinogenesis, MOG is expressed in the CNS on the outermost surface (external lamella) of mature myelin sheaths and on the cell surface of myelinating oligodendrocytes. MOG is thought to function as a regulator of oligodendrocyte microtubule stability and as a mediator of interactions between myelin and the immune system in the complement cascade. Although MOG is a relatively minor component of the myelin membrane, it is a primary auto- antigen target involved in the pathogenesis of immune-mediated demyelinating diseases including experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis.

The MOG 35-55 peptide is an immunodominant epitope of MOG that induces strong T and B cell responses. A single injection of this peptide fragment can produce an exacerbating-remitting neurologic disease with extensive plaque-like demyelination, which may serve as a model for investigating multiple sclerosis.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 0.1-2ug/ml
Western Blot: 1-5ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceMouseRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to MOG 35-55aa of mouse MOG (KLH).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Specificity:
Recognizes mouse MOG.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Pham-Dinh, D (1995) Genomics 29: 345- 352. 2. Pham-Dinh, D. (1995) Immunogenetics 42: 386-391. 3. Pham- Dinh, D (1993) PNAS 90: 7990-7994. 4. Roth, M.-P (1995) Genomics 28: 241-250. 5. Ichikawa M (1996) J. Immunol. 157, 919-926. 6. Bernard CC (1997) J. Mol. Med. 75, 77-87. 7. Slavin A (1998) Autoimmunity 28, 109-120.